0001299130-21-000053.txt : 20210217 0001299130-21-000053.hdr.sgml : 20210217 20210217211735 ACCESSION NUMBER: 0001299130-21-000053 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210212 FILED AS OF DATE: 20210217 DATE AS OF CHANGE: 20210217 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LIVINGSTON RANDALL S CENTRAL INDEX KEY: 0001235118 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34899 FILM NUMBER: 21647403 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PACIFIC BIOSCIENCES OF CALIFORNIA, INC. CENTRAL INDEX KEY: 0001299130 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 161590339 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1305 O'BRIEN DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650-521-8000 MAIL ADDRESS: STREET 1: 1305 O'BRIEN DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 FORMER COMPANY: FORMER CONFORMED NAME: PACIFIC BIOSCIENCES OF CALIFORNIA INC DATE OF NAME CHANGE: 20050829 FORMER COMPANY: FORMER CONFORMED NAME: NANOFLUIDICS INC DATE OF NAME CHANGE: 20040729 4 1 certent-form4.xml PRIMARY DOCUMENT X0306 4 2021-02-12 0001299130 PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB 0001235118 LIVINGSTON RANDALL S PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 1305 O'BRIEN DRIVE MENLO PARK CA 94025 1 0 0 0 Common Stock 2021-02-12 4 M 0 17500 10.58 A 17500 D Common Stock 2021-02-12 4 M 0 25000 1.83 A 42500 D Common Stock 2021-02-12 4 M 0 25000 2.54 A 67500 D Common Stock 2021-02-12 4 S 0 67500 48.066 D 0 D Stock Option (right to buy) 10.58 2021-02-12 4 M 0 17500 0 D 2021-06-23 Common Stock 17500 0 D Stock Option (right to buy) 1.83 2021-02-12 4 M 0 25000 0 D 2022-06-13 Common Stock 25000 0 D Stock Option (right to buy) 2.54 2021-02-12 4 M 0 25000 0 D 2023-05-21 Common Stock 25000 0 D This sale price represents the weighted average sale price of the shares sold ranging from $48.00 to $48.70 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. The shares subject to the option are fully vested and exercisable. /s/ Brett Atkins, Attorney-in fact 2021-02-17